Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer

Abstract excerpt

PURPOSE Atypical, non-V600 BRAF ( aBRAF ) mutations represent a rare molecular subtype of metastatic colorectal cancer (mCRC). Preclinical data are used to categorize aBRAF mutations into class II (intermediate to high levels of kinase activity, RAS independent) and III (low kinase activity level, RAS dependent). The clinical impact of these mutations on anti-EGFR treatment efficacy is unknown. PATIENTS AND...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Research and Treatments
• Share to Colorectal Cancer Treatments and Studies
• Share to Melanoma and MAPK Pathways